Pharmanutra (PHN) Company presentation summary

Profile and scale

• Founded in Pisa in 2003; operates across pharmaceuticals, nutraceuticals, sports nutrition and diagnostics, with products in 81 countries.

• At 30 June 2026: 144 employees, average age 41, with 54% women and 46% men.

• Portfolio and research assets include 23 proprietary raw materials, 28 patents, 59 registered trademarks and 204 clinical studies and publications.

• Five entities span Italy, the U.S. and Spain, including Akern and Athletica Cetilar; Athletica Cetilar is a joint venture in which Athletica S.n.c. holds 30%.

Research and proprietary technologies

• Research focuses on micronutrient deficiencies, joint and muscle health, sports nutrition and body-composition analysis.

• Sucrosomial Technology protects micronutrients and supports intestinal absorption; applications include iron, magnesium, zinc, vitamins and other nutrients.

• In 2025, WHO recognized Sucrosomial Technology in its Patient Blood Management guidelines; Sucrosomial iron is identified as the only oral food supplement recommended there for iron-deficiency anaemia in patients with cardiovascular disease and diabetes.

• Cetylated Fatty Acids support joint and muscle function; topical products contain up to 7.5% CFA, while oral Lipocet received a patent in 2022 as a Novel Food.

• Akern develops bioimpedance diagnostic devices and software for body-composition assessment across clinical, sports and nutritional settings.

Operating model and commercial reach

• Vertical integration covers proprietary raw-material development, formulation, production oversight and distribution, supporting quality, traceability and shorter time to market.

• International sales use 53 distributors across 81 countries; direct subsidiaries operate in the U.S. and Spain, while China is served through cross-border e-commerce.

• Italy combines specialist sales networks with digital channels; an online store launched in 2023 and an Amazon storefront in 2025.

• 27 new products launched in the Italian market over the three years preceding the presentation.